Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siv Jönsson

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 28, 2005
Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drugSiv Jönsson, Mats O Karlsson
Clinical Pharmacology and Therapeutics|January 25, 2003
A rational approach for selection of optimal covariate-based dosing strategiesSiv Jönsson, Mats O Karlsson
European Journal of Clinical Pharmacology|June 27, 2009
Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia ASven Björkman, Anna Folkesson, Siv Jönsson
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 4, 2019
Model-based evaluation of low-dose factor VIII prophylaxis in haemophilia AAri Brekkan, Johanna Degerman, Siv Jönsson
Molecular Pharmaceutics|February 23, 2016
Exploring Factors Causing Low Brain Penetration of the Opioid Peptide DAMGO through Experimental Methods and ModelingAnnika Lindqvist, Siv Jönsson, Margareta Hammarlund-Udenaes
Journal of Pharmacokinetics and Pharmacodynamics|November 26, 2004
Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXEDSiv Jönsson, Maria C Kjellsson, Mats O Karlsson
Pharmaceutical Research|March 18, 2021
Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan SafetyIris K Minichmayr, Mats O Karlsson, Siv Jönsson
The AAPS Journal|March 12, 2005
The back-step method--method for obtaining unbiased population parameter estimates for ordered categorical dataMaria C Kjellsson, Siv Jönsson, Mats O Karlsson
Clinical Pharmacokinetics|January 20, 2012
Role of modelling and simulation: a European regulatory perspectiveSiv Jönsson, Anja Henningsson, Monica Edholm, et al.
Journal of Clinical Pharmacology|November 1, 2008
Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk functionAnders Viberg, Otto Cars, Mats O Karlsson, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 28, 2005
Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drugSiv Jönsson, Mats O Karlsson
Clinical Pharmacology and Therapeutics|January 25, 2003
A rational approach for selection of optimal covariate-based dosing strategiesSiv Jönsson, Mats O Karlsson
European Journal of Clinical Pharmacology|June 27, 2009
Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia ASven Björkman, Anna Folkesson, Siv Jönsson
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 4, 2019
Model-based evaluation of low-dose factor VIII prophylaxis in haemophilia AAri Brekkan, Johanna Degerman, Siv Jönsson
Molecular Pharmaceutics|February 23, 2016
Exploring Factors Causing Low Brain Penetration of the Opioid Peptide DAMGO through Experimental Methods and ModelingAnnika Lindqvist, Siv Jönsson, Margareta Hammarlund-Udenaes
Journal of Pharmacokinetics and Pharmacodynamics|November 26, 2004
Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXEDSiv Jönsson, Maria C Kjellsson, Mats O Karlsson
Pharmaceutical Research|March 18, 2021
Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan SafetyIris K Minichmayr, Mats O Karlsson, Siv Jönsson
The AAPS Journal|March 12, 2005
The back-step method--method for obtaining unbiased population parameter estimates for ordered categorical dataMaria C Kjellsson, Siv Jönsson, Mats O Karlsson
Clinical Pharmacokinetics|January 20, 2012
Role of modelling and simulation: a European regulatory perspectiveSiv Jönsson, Anja Henningsson, Monica Edholm, et al.
Journal of Clinical Pharmacology|November 1, 2008
Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk functionAnders Viberg, Otto Cars, Mats O Karlsson, et al.
Pageof 5